2 completed, 1 unknown, 1 withdrawn. 4 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 2 |
Follow AT-007: new trials by email Literature Review of AT-007 trials Research Report on AT-007
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Confirmatory Study of Govorestat in CMT-SORD Govorestat, Placebo Control - Charcot-Marie-Tooth Disease With Sorbitol Dehydrogenase Deficiency (CMT-SORD) | Phase 3 | Withdrawn | Applied Therapeutics, Inc. | 2026-05-01 | 2026-05-29 | |
| Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency AT-007, Placebo - Hereditary Neuropathy Caused by SORD Deficiency | Phase 2 / Phase 3 | Completed | Applied Therapeutics, Inc. | 56 | 2022-01-01 | 2026-06-09 |
| AT-007 in Adult Subjects With Classic Galactosemia (CG) AT-007 - Classic Galactosemia | Phase 3 | Unknown | Applied Therapeutics, Inc. | 7 | 2021-10-01 | 2022-06-14 |
| Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia AT-007, Placebo - Classic Galactosemia | Phase 2 / Phase 3 | Completed | Applied Therapeutics, Inc. | 47 | 2021-03-20 | 2025-10-29 |
Galactosemias (2)
Applied Therapeutics, Inc. (4)
United States (4) · Italy (2) · Australia (1) · Czechia (1) · France (1) · Germany (1) · Spain (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Jonathan W Mink, MD (1) · Michael E Shy, MD (1) · Susan E Waisbren, PhD (1)